JPWO2020036995A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020036995A5 JPWO2020036995A5 JP2021506715A JP2021506715A JPWO2020036995A5 JP WO2020036995 A5 JPWO2020036995 A5 JP WO2020036995A5 JP 2021506715 A JP2021506715 A JP 2021506715A JP 2021506715 A JP2021506715 A JP 2021506715A JP WO2020036995 A5 JPWO2020036995 A5 JP WO2020036995A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- lymphoma
- heterocyclyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 11
- 230000000155 isotopic effect Effects 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 201000003444 follicular lymphoma Diseases 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- -1 heteroalkenylene Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718925P | 2018-08-14 | 2018-08-14 | |
| US62/718,925 | 2018-08-14 | ||
| PCT/US2019/046405 WO2020036995A1 (en) | 2018-08-14 | 2019-08-13 | Combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534114A JP2021534114A (ja) | 2021-12-09 |
| JPWO2020036995A5 true JPWO2020036995A5 (https=) | 2022-08-19 |
| JP2021534114A5 JP2021534114A5 (https=) | 2022-08-19 |
Family
ID=69525833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506715A Pending JP2021534114A (ja) | 2018-08-14 | 2019-08-13 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210161909A1 (https=) |
| JP (1) | JP2021534114A (https=) |
| CN (1) | CN112839651A (https=) |
| AU (1) | AU2019322858A1 (https=) |
| EA (1) | EA202190360A1 (https=) |
| IL (1) | IL280729A (https=) |
| MX (1) | MX2021001764A (https=) |
| TW (1) | TW202021592A (https=) |
| WO (1) | WO2020036995A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| AU2023228576A1 (en) * | 2022-03-01 | 2024-09-26 | Mei Pharma, Inc. | Combination therapy of pi3k inhibitor and pd-1 inhibitor |
| CN118949002A (zh) * | 2024-10-15 | 2024-11-15 | 杭州阿克索生物科技有限责任公司 | 一种宫颈癌细胞抑制组合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563596B2 (en) * | 2006-06-21 | 2013-10-22 | Piramal Enterprises Limited | Enantiomerically pure compounds for the treatment of proliferative disorders |
| ES2608967T3 (es) * | 2011-03-28 | 2017-04-17 | Mei Pharma, Inc. | (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas |
| WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| TW201618773A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| RU2726367C2 (ru) * | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| CN109982687A (zh) * | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| US11304953B2 (en) * | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 US US17/268,049 patent/US20210161909A1/en not_active Abandoned
- 2019-08-13 WO PCT/US2019/046405 patent/WO2020036995A1/en not_active Ceased
- 2019-08-13 JP JP2021506715A patent/JP2021534114A/ja active Pending
- 2019-08-13 MX MX2021001764A patent/MX2021001764A/es unknown
- 2019-08-13 EA EA202190360A patent/EA202190360A1/ru unknown
- 2019-08-13 AU AU2019322858A patent/AU2019322858A1/en not_active Abandoned
- 2019-08-13 CN CN201980067618.0A patent/CN112839651A/zh active Pending
- 2019-08-14 TW TW108128842A patent/TW202021592A/zh unknown
-
2021
- 2021-02-08 IL IL280729A patent/IL280729A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517116A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| RU2344123C9 (ru) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора | |
| JP2020517616A5 (https=) | ||
| JP2019529419A5 (https=) | ||
| JP2019522007A5 (https=) | ||
| JP2020537645A5 (https=) | ||
| JP2021512087A5 (https=) | ||
| JP2007501793A5 (https=) | ||
| JPWO2021245055A5 (https=) | ||
| JP2008508214A (ja) | 女性の性障害の治療用ピペラジン誘導体 | |
| JPWO2022235822A5 (https=) | ||
| JP2020505402A5 (https=) | ||
| JP2013520473A5 (https=) | ||
| JP2022071077A5 (https=) | ||
| JP2021523169A5 (https=) | ||
| RU2000125568A (ru) | Производные циклоалкенов, их получение и применение | |
| JP2020521739A5 (https=) | ||
| JPWO2019183226A5 (https=) | ||
| JPWO2023106310A5 (https=) | ||
| JP2020128426A5 (https=) | ||
| JP2013528619A5 (https=) | ||
| JP2014521609A5 (https=) | ||
| JPWO2020023560A5 (https=) | ||
| JPWO2019149164A5 (https=) |